January 18, 2017 07:29 AM ESTUpdated 09:48 AM
Deals

Eli Lil­ly nabs CoLu­cid and a PhI­II mi­graine drug in $960M buy­out

John Carroll

Editor & Founder

Eli Lil­ly’s new CEO has pulled off his first M&A deal.

The phar­ma gi­ant $LLY is buy­ing CoLu­cid $CLCD for $960 mil­lion, adding some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times